Acute Otitis Media Treatment Market, by Drug Type, Formulation, End User, and Region - Global Trends, and Forecast, 2022 - 2028

Acute Otitis Media Treatment Market, by Drug Type, Formulation, End User, and Region - Global Trends, and Forecast, 2022 - 2028

Acute otitis media (AOM) is inflammation of the fluid in the middle ear. AOM is the most common infection and mainly caused in children under the age of 7 years. According to an article published American Family Physician Journal in 2013, around 80% of children will have at least one episode of acute otitis media (AOM) before their school age. AOM is mainly caused by bacteria such as Streptococcus pneumoniae (strep) and Hemophilus influenzae (H. flu) and viruses. Bacteria account for 85% cases of AOM and viruses account for only 15%. AOM is mostly treated with antibiotics usually for 7–10 days and with some analgesic and anesthetic in order to the reduce pain.
Market Dynamics
Increasing prevalence of acute otitis media is expected to be a major driver for growth of the market. Acute otitis media is a very common disease and occurs mostly in children, therefore, increasing prevalence of this disease is expected to increase demand for treatment drugs, thereby positively affecting market growth. According to an article published in The Journal of Laryngology & Otology, in 2013, prevalence of otitis media subtypes is between 7.1–12.8%. Furthermore, recent launches and FDA approvals for new drugs for the treatment of acute otitis media is also expected to drive the market growth in the near future. For instance, in 2015, Otonomy, Inc. received U.S. Food and Drug Administration (FDA) approval for its OTIPRIO (ciprofloxacin otic suspension) indicated for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement. In 2021, Otonomy, Inc. launched OTIPRIO in U.S. market.
Key features of the study:

This report provides in-depth analysis of acute otitis media treatment market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
It profiles leading players in the global acute otitis media treatment market  based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies, and future plans
Key companies covered as a part of this study include Pfizer, Inc., Eli Lilly and Company, Abbott Laboratories, GlaxoSmithKline plc., Bayer AG, Novartis AG, Pediapharm Inc., Sanofi S.A., and Bristol Myers Squibb Company.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
The global acute otitis media treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the acute otitis media treatment market

Detailed Segmentation:

Global Acute Otitis Media Treatment Market, By Drug Type :

Antibiotics
Nonsteroidal anti-Inflammatory drug
Analgesic
Anaesthetic

Global Acute Otitis Media Treatment Market, By Formulation:

Oral
Topical

Global Acute Otitis Media Treatment Market, By Distribution Channel:

Hospital
Retail pharmacies
Online pharmacies

Global Acute Otitis Media Treatment Market, By Geography:

North America

By Drug Type :

Antibiotics
Nonsteroidal anti-Inflammatory drug
Analgesic
Anaesthetic

By Formulation

Oral
Topical

By Distribution Channel:

Hospital
Retail pharmacies
Online pharmacies

By Country:

U.S.
Canada

Europe

By Drug Type :

Antibiotics
Nonsteroidal anti-Inflammatory drug
Analgesic
Anaesthetic

By Formulation

Oral
Topical

By Distribution Channel:

Hospital
Retail pharmacies
Online pharmacies

By Country:

U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe

Asia Pacific

By Drug Type :

Antibiotics
Nonsteroidal anti-Inflammatory drug
Analgesic
Anaesthetic

By Formulation

Oral
Topical

By Distribution Channel:

Hospital
Retail pharmacies
Online pharmacies

By Country:

China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific

Latin America

By Drug Type :

Antibiotics
Nonsteroidal anti-Inflammatory drug
Analgesic
Anaesthetic

By Formulation

Oral
Topical

By Distribution Channel:

Hospital
Retail pharmacies
Online pharmacies

By Country:

Brazil
Mexico
Rest of Latin America

Middle East

By Drug Type :

Antibiotics
Nonsteroidal anti-Inflammatory drug
Analgesic
Anaesthetic

By Formulation

Oral
Topical

By Distribution Channel:

Hospital
Retail pharmacies
Online pharmacies

By Country:

GCC
Israel
Rest of Middle East

Africa

By Drug Type :

Antibiotics
Nonsteroidal anti-Inflammatory drug
Analgesic
Anaesthetic

By Formulation

Oral
Topical

By Distribution Channel:

Hospital
Retail pharmacies
Online pharmacies

By Country:

Central Africa
South Africa
North Africa

Company Profiles

Pfizer, Inc.*

Company Overview
Product Portfolio
Financial Performance
Key Strategies
Recent Developments

Eli Lilly and Company
Abbott Laboratories
GlaxoSmithKline plc.
Bayer AG
Novartis AG
Pediapharm Inc.
Sanofi S.A.
Bristol Myers Squibb Company

 “*” marked represents similar segmentation in other categories in the respective section.